PhD Scientific Days 2024

Poster Session P - Conservative Medicine

Lung Transplantation for IPF Patients in the EMPIRE Countries

Előadó neve

Dr. Tóth, Nóra Melinda

Neptun code

ALV8KB

Előadó munkahelye

Department of Pulmonology, Semmelweis University

Előadó telefonszáma

+36206663433

Előadó e-mail címe

toth.nora1@semmelweis.hu

Az előadás címe

Lung Transplantation for IPF Patients in the EMPIRE Countries

Szerző(k) neve és munkahelye

Nóra Melinda Tóth¹, Mordechai R. Kramer², Martina Šterclová³, Veronika Müller¹, Katarzyna Lewandowska⁴, Nesrin Mogulkoc⁵, Marta Hájková⁶, Michael Studnicka⁷, Jasna Tekavec-Trkanjec⁸, Dragana Jovanovic⁹, Anton Penev¹⁰, Zoran Arsovski¹¹, Jakub Gregor¹², Petra Ovesná¹²

1: Department of Pulmonology, Semmelweis University, Budapest, Hungary
2: Institute of Pulmonary Medicine, Rabin Medical Center, Petah Tikva, Israel
3: Department of Respiratory Medicine, Thomayer University Hospital, Prague, Czech Republic
4: First Department of Pulmonary Diseases, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
5: Department of Pulmonary Medicine, Ege University Medical School, Izmir, Turkey
6: Clinic of Pneumology and Phthisiology, University Hospital Bratislava, Bratislava, Slovakia
7: Department of Respiratory Medicine, Paracelsus Medical University, Salzburg, Austria
8: Pulmonary Department, University Hospital Dubrava, Zagreb, Croatia
9: Internal Medicine Clinic Akta Medica, Belgrade, Serbia
10: Pulmonary Department, Acibadem City Clinic Tokuda Hospital Sofia, Sofia, Bulgaria
11: PHI University Clinic of Pulmonology and Allergy, Skopje, Macedonia
12: Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

Bemutatás módja

Poszter

Szekció

Poster Session P - Conservative Medicine

Language of the presentation

English

Preferred session

Conservative Medicine

Összefoglaló szövege

Introduction: Idiopathic pulmonary fibrosis (IPF) is one of the leading causes of lung transplantation (LuTX) worldwide, yet there are no data on LuTX in these patients in the Central and Eastern European (CEE) region.

Aim: We aimed to identify factors influencing LuTX referral in this region.

Methods: We analyzed baseline characteristics of IPF patients potentially eligible for transplant at the time of their enrollment into the of European MultiPartner IPF Registry (EMPIRE) between 2012 and 2022 (n = 1,256). Transplanted (n = 94) and potentially eligible but not transplanted (n = 1,162) subgroups were compared.

Results: In total, 7.5% of the potentially eligible patients underwent LuTX, with Israel having the highest proportions (43.1%), followed by Austria (9.5%), Hungary (7.8%) and the Czech Republic (4.6%). Transplanted patients were significantly younger (60.2 ± 7.4 vs. 62.6 ± 6.2 years, p <0.001), and had worse lung function (FVC 60 ± 15% vs. 74 ± 21%; p <0.001, TLCO 41 ± 15% vs. 49 ± 19%; p <0.001) compared to the non-transplanted group at inclusion into the registry. Additionally, they were treated more often with antifibrotics and were more likely to receive long-term oxygen therapy at baseline.

Conclusion: LuTX rates for IPF are low in the CEE countries, patients presenting in younger age and with a more advanced disease are more likely to undergo LuTX.

Funding: Nóra M. Tóth was granted by the SE 250+ Excellence PhD Scholarship. The EMPIRE registry was supported by Boehringer Ingelheim and Roche. This specific study has not been funded.

University

Semmelweis University

Supervisor

Prof. Dr. Veronika Müller

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6871

Start

16:35

End

16:38